Confo Therapeutics employs a proprietary discovery platform using conformation-specific ConfoBodies® to stabilize GPCRs in functionally relevant states and discover small molecules and agonistic antibodies. The company is building a pipeline focused on metabolic and endocrine diseases, including programs directed at obesity and severe rare endocrine disorders. Confo plans to advance two wholly owned programs through Phase 1 and bring two additional programs to IND approval, with explicit efforts on molecules targeting GPR75 for obesity. The company emphasizes both small-molecule GPCR modulators and therapeutic antibodies, notably agonistic antibodies. Confo is headquartered in Ghent, Belgium. Its current financial position includes the recently closed EUR 60M Series B financing to accelerate its development pipeline. Confo Therapeutics develops ConfoBodyTM single-domain camelid antibodies that selectively stabilize G-protein coupled receptors (GPCRs) to enable drug discovery. The company is building a portfolio of first-in-class programs based on its Confo® technology. It operates both internal discovery programs and revenue-generating partnerships with pharma on non-competing GPCR targets. Confo Therapeutics has active collaborations with Lundbeck and Roche to apply its platform. The firm plans to use new capital to advance its pipeline of GPCR-modulating compounds toward clinical candidates. The company was co-founded in 2015 as a VUB–VIB spin-off and is based in Ghent, Belgium. Confo Therapeutics is an emerging drug-discovery company based in Ghent, Belgium, that uses its proprietary Confo® technology to discover new GPCR agonist compounds for the treatment of fibrosis. The company operates a Drug Discovery Center in Gent and a Target Discovery Center in Brussels. It is expanding the applicability of its Confo® platform, supported by recent grant awards. Financially, Confo Therapeutics has been awarded non-dilutive funding totaling roughly €2.6 million to support its discovery programs. Part of the funding will be allocated over a two-year VLAIO grant primarily to the Gent Drug Discovery Center, while the Innoviris award will support work at the Brussels Target Discovery Center. The company’s near-term plans, as described in the awards, focus on fibrosis compound discovery and broadening the Confo® technology’s use.

Total raised

$100M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2024